Antipodes Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Antipodes Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Buy	235 +108	+85%	+$47.9K	﹤0.01%	102
2026 Q1	$56.7K	Hold	127	–	–	﹤0.01%	105
2025 Q4	$57.6K	Buy	+127	New	+$54.7K	﹤0.01%	103
2025 Q3	–	Sell	-241	Closed	-$107K	–	137
2025 Q2	$107K	Sell	241 -14	-5%	-$6.45K	﹤0.01%	73
2025 Q1	$124K	Buy	+255	New	+$119K	﹤0.01%	68
2024 Q4	–	Sell	-127,853	Closed	-$59.5M	–	95
2024 Q3	$59.5M	Buy	127,853 +558	+0.4%	+$268K	2.06%	22
2024 Q2	$59.7M	Sell	127,295 -62,105	-33%	-$27M	2.17%	21
2024 Q1	$78.2M	Buy	189,400 +100,480	+113%	+$42.5M	2.47%	19
2023 Q4	$36.2M	Buy	+88,920	New	+$32.8M	1.13%	29

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Antipodes Partners's VRTX Position: Q2 2026 in Review

Antipodes Partners increased its Vertex Pharmaceuticals (VRTX) stake by 85% in Q2 2026, buying an estimated $47.9K and bringing the position to 235 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #102.

Antipodes Partners first reported a position in VRTX in Q4 2023 and has held it in 9 quarters since. The position peaked at $78.2M in Q1 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Antipodes Partners held 235 shares of Vertex Pharmaceuticals worth $117K as of Q2 2026.
Antipodes Partners bought 108 Vertex Pharmaceuticals shares in Q2 2026, an estimated $47.9K.
Vertex Pharmaceuticals made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #102 holding.
Antipodes Partners first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
Antipodes Partners's Vertex Pharmaceuticals position peaked at $78.2M in Q1 2024.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.